Logo image of RVLP

RVL PHARMACEUTICALS PLC (RVLP) Stock Price, Quote, News and Overview

NASDAQ:RVLP - Nasdaq - IE00BF2HDL56 - Common Stock - Currency: USD

0.0282  -0.01 (-32.05%)

After market: 0.0223 -0.01 (-20.92%)

RVLP Quote, Performance and Key Statistics

RVL PHARMACEUTICALS PLC

NASDAQ:RVLP (10/20/2023, 8:09:06 PM)

After market: 0.0223 -0.01 (-20.92%)

0.0282

-0.01 (-32.05%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.91
52 Week Low0.03
Market Cap3.14M
Shares111.41M
Float83.67M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-08 2023-11-08/bmo
IPO10-12 2018-10-12


RVLP short term performance overview.The bars show the price performance of RVLP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

RVLP long term performance overview.The bars show the price performance of RVLP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RVLP is 0.0282 USD. In the past month the price decreased by -71.8%. In the past year, price decreased by -98.37%.

RVL PHARMACEUTICALS PLC / RVLP Daily stock chart

RVLP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.62 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About RVLP

Company Profile

RVLP logo image RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 125 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The firm is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Company Info

RVL PHARMACEUTICALS PLC

400 Crossing Boulevard

Bridgewater NEW JERSEY US

Employees: 125

Company Website: https://www.rvlpharma.com/

Phone: 19088091300.0

RVL PHARMACEUTICALS PLC / RVLP FAQ

What is the stock price of RVL PHARMACEUTICALS PLC today?

The current stock price of RVLP is 0.0282 USD. The price decreased by -32.05% in the last trading session.


What is the ticker symbol for RVL PHARMACEUTICALS PLC stock?

The exchange symbol of RVL PHARMACEUTICALS PLC is RVLP and it is listed on the Nasdaq exchange.


On which exchange is RVLP stock listed?

RVLP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RVL PHARMACEUTICALS PLC stock?

9 analysts have analysed RVLP and the average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282. Check the RVL PHARMACEUTICALS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RVL PHARMACEUTICALS PLC worth?

RVL PHARMACEUTICALS PLC (RVLP) has a market capitalization of 3.14M USD. This makes RVLP a Nano Cap stock.


How many employees does RVL PHARMACEUTICALS PLC have?

RVL PHARMACEUTICALS PLC (RVLP) currently has 125 employees.


Is RVL PHARMACEUTICALS PLC (RVLP) expected to grow?

The Revenue of RVL PHARMACEUTICALS PLC (RVLP) is expected to decline by -28.9% in the next year. Check the estimates tab for more information on the RVLP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RVL PHARMACEUTICALS PLC (RVLP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RVL PHARMACEUTICALS PLC (RVLP) stock pay dividends?

RVLP does not pay a dividend.


When does RVL PHARMACEUTICALS PLC (RVLP) report earnings?

RVL PHARMACEUTICALS PLC (RVLP) will report earnings on 2023-11-08, before the market open.


What is the Price/Earnings (PE) ratio of RVL PHARMACEUTICALS PLC (RVLP)?

RVL PHARMACEUTICALS PLC (RVLP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).


RVLP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RVLP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RVLP. Both the profitability and financial health of RVLP have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RVLP Financial Highlights

Over the last trailing twelve months RVLP reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 27.84% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -79.93%
ROE -418.14%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-71.43%
Sales Q2Q%-2.25%
EPS 1Y (TTM)27.84%
Revenue 1Y (TTM)5.64%

RVLP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to RVLP. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 27.9% and a revenue growth -28.9% for RVLP


Ownership
Inst OwnersN/A
Ins Owners5.54%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.22
Price Target3.21 (11282.98%)
EPS Next Y27.9%
Revenue Next Year-28.9%